The p53 tumor suppressor belongs to a gene family that includes two other structurally and functionally related members: p73 and p63. The regulation of p53 activity differs significantly from that of p73 and p63. To enhance the tumor suppressive activity of p53, we constructed six recombinant adenoviruses that encode hybrid proteins with three functional domains derived from either p53 or TAp63g. The potency of these hybrid molecules in suppressing tumorigenesis was evaluated using in vitro and in vivo models. Of the hybrid molecules tested, one hybrid named p63-53O was the most potent activator of apoptosis in human cancer cells. The p63-53O hybrid is composed of the transcriptional activation domain and DNA-binding domain of TAp63g and the oligomerization domain of p53. The p63-53O hybrid efficiently transactivated p53AIP1. Moreover, silencing of p53AIP1 partially abolished the apoptotic response to p63-53O in human cancer cells. The p53-p63 hybrid molecule is a novel potent anti-proliferative agent for the treatment of cancer.
INTRODUCTION
The tumor suppressor gene p53 encodes a transcriptional activator that is central to cellular responses to DNA damage, and oncogenic and cellular stress. 1 The majority of cancer-associated mutations in p53 are missense mutations in the DNA-binding domain (DBD). These mutations typically lead to the expression of a full-length mutant protein (mutant p53) that is incapable of transactivating p53 target genes. 1, 2 In addition to the loss of wild-type activity, many p53 mutants also function as dominant-negative proteins that inactivate wild-type p53 expressed from the remaining wildtype allele. 3 Although controversial, the presence of mutant p53 in cancer cells is associated with more aggressive tumors and therefore worse outcomes. 4, 5 The exogenous expression of p53 inhibits cancer cell growth by hindering cell cycle progression and inducing apoptosis. In many cancer types, the loss of p53 causes not only tumor development but also chemoresistance. 6 Therefore, reintroducing wild-type p53 into tumor cells activates growth inhibitory pathways that sensitize tumor cells to chemotherapeutics. Indeed, p53-based gene therapy has proven effective against several types of cancers. However, amplification of MDM2, mutational inactivation of p14ARF, or the presence of the HPV E6 oncogene in HPV-positive cervical cancer disable the p53 growth suppression pathway and thereby render p53-based gene therapy ineffective. [7] [8] [9] [10] [11] The p53 gene family consists of three members, p53, p63 and p73, which share homology in three domains: the N-terminal transcriptional activation domain (TAD), the central core sequencespecific DBD and the C-terminal oligomerization domain (OLD). However, p53 family members show distinct patterns of transcriptional and post-transcriptional regulation. [12] [13] [14] [15] p53 is transcribed ubiquitously at a relatively high level, and the amount of p53 protein in normal cells is determined primarily by its degradation rate. The proteolytic degradation of p53 is mediated by MDM2, which ubiquitinates p53. The phosphorylation of amino-acid residues at the N-terminus of p53 does not affect its DNAbinding activity but does affect its affinity for MDM2 and therefore its subsequent degradation. 16, 17 The structure of p63 is more complex than that of p53. 18 The p63 gene is expressed as multiple isoforms with different N and C termini that result from the use of two different promoters and alternative splicing. p63 isoforms may possess one of the two N termini: one is transcriptionally active (TA), and the other has an N-terminal deletion (DN). In addition, the C termini vary between isoforms. In particular, p63a isoform contains a C-terminal region that drastically reduces their activity. The functional differences among p63 isoforms may be due to the differential regulation of alternative promoters and splicing. DN variants lack the TAD and are transcribed from an internal promoter within exon 3 of the full-length gene. The TA isoforms function similar to p53 in cultured cells, transactivating certain p53 target genes and inducing apoptosis. In contrast, the DN isoforms are thought to have a role in inhibiting target gene transactivation by p53 and the TA isoforms of p63. The TA isoforms may exhibit tumor suppressor functions, whereas the increased expression of the DN isoforms has the potential to be oncogenic.
However, the extent of TAp63 and TAp73 function in tumor suppression remains unclear. Mutations in p63 and p73 are not commonly observed in human tumors, but several lines of evidence suggest that p63 and p73 mediate cellular responses to DNA-damage agents and possess in vivo tumor suppressor activity. [18] [19] [20] [21] [22] When overexpressed, TAp63 and TAp73 activate several common p53-responsive genes involved in cell cycle arrest and apoptosis. In addition, in one genetic background, mice heterozygous for p63 and p73 developed tumors. 23 In this study, we constructed six p53 and TAp63g hybrid genes by connecting the coding sequences of protein functional domains. Importantly, p63-53O, which contains the TAD and DBD of TAp63 and the OLD of p53, induced apoptosis more effectively than either p53 or TAp63g in in vitro and in vivo models. We also demonstrated that p53AIP1 expression was upregulated more effectively by p63-53O than by p53 or TAp63g. Our results indicate that this hybrid gene could be used in a novel approach to cancer treatment.
MATERIALS AND METHODS

Cell lines and cell culture
The 11 human cancer cell lines used in this study were purchased from the American Type Culture Collection (Manassas, VA) or the Japanese Collection of Research Bioresources (Osaka, Japan). All cells were cultured under the conditions recommended by their respective depositors.
Construction of hybrid molecules of p53 and TAp63g
The full-length versions of p53 and TAp63g in the plasmid pCMV-Tag2 have been described previously. 24, 25 p53-p63 hybrids were generated by swapping the three domains of p53 and TAp63g using the overlapping extension method. 26, 27 These genes were constructed in-frame to allow for FLAG epitope tagging at the N-terminus. The cDNAs encoding the hybrid molecules were sequenced to verify their identity. Additional information on the construction of the expression vectors, including the primer sequences used in PCR amplification, is available upon request. The procedures for the generation, purification and infection of replicationdeficient recombinant adenoviruses were described previously. 28 We used the replication-deficient E1-deleted Ad5 vector pJM17 (Microbix Biosystem, Toronto, Ontario, Canada) as a backbone; the corresponding genes were expressed under the control of a human cytomegalovirus promoter/ enhancer and a bovine growth hormone polyadenylation signal. Adenovirus titer in plaque-forming units (p.f.u.) was determined by plaque-formation assays following the infection of 293T cells. The multiplicity of infection (MOI) was defined as the ratio of the total number of p.f.u. introduced to the total number of cells infected. We performed adenovirus tittering for duplicate samples to confirm the experimental reproducibility. Controls containing the bacterial lacZ gene (Ad-lacZ) or the GFP gene (Ad-GFP) were described previously. 24, 25, 28 Detection of apoptosis Cells were plated in T25 flasks at a density of 5 Â 10 5 cells per flask. Twentyfour hours later, the cells were incubated with purified virus in 1 ml of medium containing 1% FCS and agitated every 10 min for 60 min. For flow cytometry analysis, cells were harvested by trypsinization and pelleted by centrifugation at various times after infection. Pelleted cells were fixed in 90% cold ethanol, treated with RNase A (500 units ml À 1 ), and stained with propidium iodide (50 mg ml À 1 ). Samples were analyzed on a FACSCalibur flow cytometer (Becton-Dickinson, Franklin Lakes, NJ). Experiments were repeated at least three times, and 50 000 events were analyzed for each sample. Data were analyzed using the ModFIT program (Becton-Dickinson).
Caspase activity was determined with a colorimetric assay using caspase-3 assay kits (BioVision, Mountain View, CA) according to the manufacturer's protocol. These kits utilize synthetic tetrapeptides labeled with p-nitroanilide. Briefly, the cells were lysed in the supplied lysis buffer. The supernatants were collected and incubated at 37 1C with the supplied reaction buffer, which contains dithiothreitol and substrates. The caspase activity was determined by measuring the change in absorbance at 405 nm using a microplate reader.
Immunoblot analysis
Immunoblot analysis was performed as described previously. 24 The primary antibodies used for immunoblotting in this study were as follows: mouse anti-FLAG monoclonal antibody (mAb, #6106; Sigma, St Louis, MO), mouse anti-human p21 mAb (F5, Santa Cruz Biotech, Santa Cruz, CA), mouse antihuman MDM2 mAb (SMP14, Santa Cruz Biotechnology), mouse anti-human PARP mAb (BD Pharmingen, San Diego, CA), mouse anti-human caspase-9 mAb (BD Biosciences, San Jose, CA), mouse anti-human caspase-3 mAb (BD Biosciences), rabbit anti-human p53AIP1 polyclonal Ab (AnaSpec, Fremont, CA) and mouse anti-human actin mAb (Chemicon, Temecula, CA).
Northern blot and real-time RT-PCR
For northern blot analysis, total RNA (10 mg) was separated by electrophoresis on a 1% agarose gel containing 2.2 M formaldehyde and transferred onto a nitrocellulose membrane (Schleicher & Schuell, Dassel, Germany). RNA was visualized with ethidium bromide to confirm that it was intact, loaded in similar amounts and transferred properly. Hybridization was performed as described previously. 25 cDNA probes for p53AIP1 (nucleotides (nt) 345-554) and p21 (nt 11-429) were amplified by RT-PCR and sequenced to verify their identities. For real-time PCR, total RNA was reverse-transcribed using SuperScript III (Invitrogen, Carlsbad, CA) with random primers. Quantitative RT-PCR was performed using TaqMan Gene Expression assays and a 7900HT Real-Time PCR System (Applied Biosystems, Foster City, CA) according to the manufacturer's protocol. Relative levels of gene expression were quantified using the DDC t method to calculate the ratio of target gene expression to a consistently expressed housekeeping gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The primer/probe sets used were as follows: p53AIP1 (Hs00223141_m1) and GAPDH (Hs99999905_m1). The values were normalized to their respective controls (set at 1) and presented as the mean ± standard error of three independent experiments.
Chromatin immunoprecipitation (ChIP) and luciferase assays ChIP was performed as described using the ChIP Assay Kit (Upstate Biotechnology, Lake Placid, NY). 24, 25 The amount of precipitated p53AIP1 promoter DNA was determined by PCR using oligonucleotides spanning the p53 consensus binding sites (sense, 5 0 -TGGGTAGGAGGTGATCTCACC-
0 -GCTACAAGCAAGTCGGTGCT-3 0 ) were used as a positive control. In both cases, 30 cycles of amplification were performed. For the luciferase assays, the consensus binding sequence for p53 in the human p53AIP1 gene (5 0 -TCTCTTGCCCGGGCTTGTCG-3 0 ) and a mutated form of this sequence (5 0 -TCTATTTCCCGGGATTTTCG-3 0 ) were synthesized and inserted upstream of a minimal promoter in the pGL3-promoter vector (Promega, Madison, WI). The resulting constructs were designated pGL3-p53AIP1-pro and pGL3-p53AIP1-pro-mut, respectively. A 100-bp fragment including this binding site was also cloned into the pGL3-basic vector to produce constructs designated pGL3-p53AIP1-ba and pGL3-p53AIP1-bamut, respectively. The consensus binding sequences for p53 family members within the human p21 29 (pGL3-p21, 5 0 -GAACATGTCCCAA CATGTTG-3 0 ) and JAG1 30 (pGL3-JAG1, 5 0 -AGGCTTCTTGTTCAGGCTTGCTCTG TGTGAACCAGACCGTTGTGCTTGGCT-3 0 ) genes and their mutant forms were also synthesized and inserted upstream of a minimal promoter in the pGL3-promoter vector (Promega). Luciferase assays were conducted as described previously. 24, 25 Animal models All animals were maintained under pathogen-free conditions and treated in accordance with the guidelines of the Animal Care and Use Committee of Sapporo Medical University. To evaluate the effects of treatment on established tumors, female BALB/c nude mice were injected subcutaneously (s.c.) in the right flank with 2 Â 10 6 SW480 cells. When the tumors reached 100 mm 3 , mice were dosed intratumorally once a day with 5 Â 10 9 p.f.u. (in 100 ml PBS) of the indicated adenoviruses for 3 or 4 consecutive days. Eight mice were included in each treatment group. Six mice of them were used for monitoring tumor formation. The other two mice were killed 5 days after treatment for in vivo TUNEL assay. The tumor volume was calculated using the equation
, where a is the largest dimension and b is the perpendicular diameter. The differences between the two groups were determined by the Student's t test on day 25. For in vivo TUNEL assay, paraffin-embedded tissue sections were deparaffinized in xylene for 5 min, rehydrated in gradient ethanol and fixed with 4% paraformaldehyde. After permeabilizing tissues with proteinase K, they were refixed with 4% paraformaldehyde. TUNEL reactions were performed using the DeadEnd Fluorometric TUNEL system (Promega) according to the manufacturer's instructions. The tissues were counterstained with DAPI (Sigma). Three different slides were examined for each tumor.
RESULTS
The pro-apoptotic potential of the p53 family Gene therapy to restore p53 function is being tested clinically for the treatment of human cancer; however, certain cancers are resistant to p53. [31] [32] [33] In colon cancer cell lines, TAp63g and TAp73b have the strongest pro-apoptotic potential of all of the p63 and p73 isoforms. 34 We introduced p53, TAp63g and TAp73b into 56 cancer cell lines using an adenoviral vector (Ad) and compared their effects on cell death and apoptosis by using flow cytometry. The sub-G1 fraction (%) contains apoptotic cells. Certain cell lines underwent apoptosis in response to p53, p73b or p63g, but approximately 25% of the cell lines were at least somewhat resistant to apoptosis induced by p53 family members. Interestingly, the apoptotic effects of TAp63g were greater than those of wild-type p53 in 15 (68.2%) of the 22 cancer cell lines that harbored endogenous wild-type p53 alleles. (Supplementary Table  S1 and Supplementary Figure S1 ). MKN45 stomach and SW480 colon cancer cells, in which the introduction of p53, p73b or p63g alone did not induce apoptosis, were infected with Ad-p53 or Ad-p63g at an MOI of 200 or with a combination of the two recombinant adenoviruses, each at the indicated MOI. At 48 h post-infection, the cells were harvested, and apoptosis was analyzed by flow cytometry, caspase activation and TUNEL assays. We observed a pro-apoptotic synergy between p53 and TAp63g gene expression (Figures 1a and b and Supplementary Figure S2a) .
We also examined the effect of combination treatment with Adp53 and Ad-p63g on the growth of human cancer xenografts. MKN45 cells were injected subcutaneously into nude mice. When the tumors reached 100 mm 3 , mice received four direct intratumoral injections of the indicated adenoviruses, one per day on days 1, 2, 3 and 4. The mice were randomly divided into four treatment groups that received individual treatment with Ad-LacZ, Ad-p53 or Ad-p63g, or a sequential combination treatment with Ad-p53 and Ad-p63g (Ad-p53 on days 1 and 3, and Ad-p63g on days 2 and 4). The growth of MKN45 xenografts was significantly inhibited by the combination treatment compared with Ad-p53 or Ad-p63g treatment alone (Po0.05; Supplementary Figure S2b) . Therefore, we concluded that cotreatment with Ad-p53 and Ad-p63g produced a strong synergistic anti-tumor effect in vitro and in vivo.
Construction of p53-p63 hybrid genes To enhance the tumor-suppressive activity of the p53 family, we generated a set of structural hybrid genes that take advantage of the differential regulation of p53 and p63 functions. The six hybrid proteins consisted of three functional domains, each derived from either p53 or TAp63g; for example, 'p53-63O' is a hybrid protein containing the N-terminal and central domains of p53 fused inframe to the C-terminal domain of p63, and 'p53-63D' is a hybrid p53 protein containing the central domain of p63. The compositions of all six hybrid proteins are shown in Figure 2 . Among the six hybrids, p63-53D localizes primarily to the cytoplasm because it lacks a typical nuclear localization signal motif. The other five hybrids mimic p53 and TAp63g and localize primarily to the nucleus, which is consistent with the presence of a nuclear localization signal (Supplementary Figure S3) . Three of the hybrid molecules (p53-63O, p63-53D and p63-53T) contain the p63 C-terminal domain but cannot oligomerize with endogenous mutant or wild-type p53. We anticipated that p53-63T and p63-53D, which contain the N-terminal domain of p63, would neither bind to MDM2 nor undergo proteosomal degradation, even though they contain the p53 central DBD. Finally, we hypothesized that p53-63D, p53-63T and p63-53O would alter the transcriptional activity of p63 because the distinct C-termini (a, b and g) of the different TAp63 isoforms are thought to modulate their ability to transactivate gene expression.
Apoptosis profiles after adenoviral-mediated expression of the p53-p63 hybrids To evaluate the anti-cancer activity of our hybrids in comparison with that of p53 and TAp63g, we created recombinant adenoviral vectors expressing FLAG-tagged human p53 (Ad-p53), TAp63g (Ad-p63g) or p53-p63 hybrids (Ad-p63-53O, Ad-p63-53D, Adp53-63T, Ad-p53-63O, Ad-p53-63D and Ad-p63-53T). The relative efficiency of adenovirus-mediated gene delivery was quantitated as the percentage of GFP-positive cells after Ad-GFP infection at an MOI of 25 to 200. According to the efficiency of gene transfer determined by GFP expression, each cell line was infected with adenovirus at the appropriate MOI. We determined whether the hybrids were equally expressed in certain cancer cell lines, such as SW480 (colon cancer), H1299 (lung cancer) and MKN45 (gastric cancer), as shown in Figure 3a . We then analyzed the induction of apoptosis in a panel of human cancer cell lines by flow cytometry. The cells were infected with adenovirus for 48 h, after which the cellular DNA content was analyzed. These data were then summarized in a histogram that depicted the percentage of sub-G1 nuclei (apoptotic cells) in a total of 5 Â 10 4 cells per population. No significant apoptotic fractions were observed in Cancer gene therapy using p53-p63 hybrids Y Sasaki et al cell lines infected with Ad-GFP. Importantly, Ad-p63-53O induced apoptosis more effectively than Ad-p53 or Ad-p63g in all four of the cell lines tested (Supplementary Figure S4) . In total, 14 cancer cell lines were analyzed by flow cytometry, and we found that p63-53O was a potent activator of apoptosis in human cancer cells regardless of the p53 status (Supplementary Table S2) .
PARP, an enzyme involved in DNA repair, is cleaved by caspase-3; consequently, the presence of cleaved PARP (85 kDa, compared with 116 kDa for the native protein) is considered a hallmark of apoptosis. The induction of apoptosis by the p53-p63 hybrid was confirmed by PARP and caspase-3/9 cleavage (Figure 3a) and by caspase-3 activity (Figure 3b ). These observations were consistent with the flow cytometry results. MKN45 cells were also infected with adenovirus at various dilutions, starting with an MOI of 50 for 48 h, and assayed for PARP cleavage and caspase-3 activity. The levels of PARP cleavage and caspase-3 activity after infection with Ad-p63-53O at an MOI of 50 were similar to those after infection with Ad-p53 or Ad-p63g at an MOI of 200 (Supplementary Figure S5) .
The therapeutic effect of intratumoral injection of p53-p63 hybrid adenovirus on the growth of subcutaneous human xenografts The in vitro results prompted us to investigate the effects of the in vivo administration of the adenoviral vectors. We established xenografts of human SW480 cells in nude mice. When the tumors reached 100 mm 3 , each mouse was given three 100 ml intratumoral injections containing 5 Â 10 9 p.f.u. of Ad-lacZ, Ad-p53, Adp63g or Ad-p63-53O, and tumor size was monitored. SW480 xenograft growth was significantly inhibited by treatment with Ad-p63-53O compared to treatment with Ad-p53 or Ad-p63g (Po0.01 at day 25; Figure 4a ). The average tumor volumes of adenovirus-treated mice on day 25 were 350 mm 3 for Ad-p53, 331 mm 3 for Ad-p63g, 102 mm 3 for Ad-p63-53O and 869 mm 3 for Figure 2 . Schematic representation of p53-p63 hybrid molecules. The wild-type p53 (unshaded) and TAp63g (black boxes) proteins are aligned at the N-terminus. The arrows indicate a junction location. The domain structure of the individual transcripts is indicated, and the TAD (transactivation domain), DBD (DNA-binding domain) and OLD (oligomerization domain) are marked: p63-53O, residues Met1 to Lys352 of TAp63g and Lys319 to Asp393 of p53; p63-53D, residues Met1 to Ser141 of TAp63g, Phe113 to Arg289 of p53, and Lys321 to Pro448 of TAp63g; p53-63T, residues Met1 to Ser141 of TAp63g and Phe113 to Asp393 of p53; p53-63O, residues Met1 to Pro318 of p53 and Lys353 to Pro448 of TAp63g; p53-63D, residues Met1 to Gly112 of p53, Phe142 to Arg320 of TAp63g, and Lys290 to Asp393 of p53; p63-53T, residues Met1 to Gly112 of p53 and Phe142 to Pro448 of TAp63g. The horizontal bars represent the nuclear localization signal (NLS). Nuclear localization of proteins in cells was predicted as NLS score by PSORT II software analysis (right, available from the PSORT web site). Caspase-3 activity was determined using a caspase-3 assay kit according to the manufacturer's protocol. Cells were infected with adenovirus and subsequently harvested and lysed at 48 h after infection. The peptidase activity of caspase-3 was measured by the cleavage of the peptide substrate DEVD-pNA. Caspase-3 activity is graphed relative to the activity in untreated cells (cont).
Ad-lacZ. Notably, Ad-p63-53O treatment induced complete tumor regression in 33% (2/6) of the tumor-bearing mice. This in vivo result correlated with the specificity observed in vitro. In addition, two animals from each treatment group were euthanized 5 days after treatment, and their tumors were harvested for in situ TUNEL assays. A marked increase in apoptosis was observed in the SW480 xenografts treated with Ad-p63-53O compared with those treated with Ad-p53 or Ad-p63g (Figure 4b ). Similar therapeutic effect of p53-p63 hybrid was observed in MKN45 xenografts (Po0.001, Supplementary Figure S6 ).
The hybrid p63-53O efficiently induces p53AIP1 transcription The hybrid p63-53O contains the residues from Met1 to Lys352 of TAp63 and Lys319 to Asp393 of p53. This hybrid contains the TAD and DBD of TAp63 and the OLD of p53. To determine whether the elevated pro-apoptotic activity of the p63-53O hybrid was due to global transcriptional activation, we investigated the induction of p53 target, including p21, MDM2, survivin, Noxa, Bax and Puma, in specific cancer cells by immunoblotting (Supplementary Figure S7) . Although the p63-53O hybrid induced a subset of p53 target genes in all three of the cell lines tested, the degree of induction was less remarkable than that by p53 or TAp63g. These results suggest that this hybrid does not act simply by increasing the transcriptional activation of p53 target genes in general.
To identify pro-apoptotic target genes specifically regulated by the hybrid p63-53O, we performed an Affymetrix Genechip analysis and compared the expression patterns of Saos-2 human osteosarcoma cells transfected with Ad-p53, Ad-p63g or Ad-p63-53O. Data are available in the GEO data base (GSE35512). One robust candidate gene identified was p53AIP1, an important target of the p53-mediated cell death response. 35 The p53AIP1 gene was reproducibly upregulated at least fourfold in p63-53O-transfected cells compared with p53-or TAp63g-transfected cells. Using p53AIP1 cDNA as a probe, we performed northern blot analyses on the Saos-2, H1299, DLD1 and SW480 human cancer cell lines. As shown in Figure 5a , the strongest induction of p53AIP1 in all of the tested cell lines was observed following Ad-p63-53O infection. We next utilized ChIP to determine whether the p63-53O hybrid protein could bind efficiently in vivo to the human p53AIP1 promoter region encompassing the p53-responsive element (p53-RE) characterized by Oda et al. 35 A ChIP assay uses specific antibodies to immunoprecipitate DNA-binding proteins along with the associated genomic DNA. We analyzed SW480 cells infected with Ad-p53, Ad-p63g, Ad-p63-53O or Ad-p63-53D. Using an anti-FLAG antibody, the DNA-protein complexes were immunoprecipitated from formaldehyde-crosslinked extracts of Ad-p53-, Ad-p63g-, Ad-p63-53O-and Ad-p63-53D-infected SW480 cells. The abundance of candidate sequences within the immunoprecipitated complexes was quantitated by PCR. As shown in Figure 5b , p63-53O was more efficiently recruited to the p53AIP1 promoter than p53 or TAp63 (top row, lane 12). As a positive control for the ChIP assay, we analyzed the MDM2 promoter. As expected, p53, TAp63g and p63-53O were immunoprecipitated with the p53-binding site within the MDM2 promoter (Figure 5b, bottom row, lanes 8, 10 and 12 ). These results indicated that the p63-53O hybrid protein efficiently binds to the p53AIP1 promoter in SW480 cells. To further evaluate the transcription-enhancing activity of p63-53O, we performed a reporter assay. The heterologous reporter vector was constructed by cloning a genomic fragment containing the p53-RE within the p53AIP1 gene upstream of the minimal SV40 promoter in the pGL3-promoter vector (pGL3-p53AIP1-pro). We also cloned a 100-bp DNA fragment corresponding to the p53-RE of the p53AIP1 gene into the pGL3-basic vector (pGL3-p53AIP1-ba). p63-53O activated both p53AIP1 luciferase reporters, whereas p53 and TAp63g activated p53AIP1 transcription less efficiently (Figure 5c ). Moreover, point mutations in the p53-RE of p53AIP1 (pGL3-p53AIP1-pro-mut and pGL3-p53AIP1-ba-mut) abolished transactivation by p63-53O. We also performed a luciferase reporter assay with the p53-RE of p21 (pGL3-p21) or JAG1, a known TAp63-target (pGL3-JAG1), cloned into the pGL3-promoter vector. The luciferase activity of pGL3-p21 was higher in cells cotransfected with p53 than in those cotransfected with p63-53O. In contrast, TAp63g and TAp73b efficiently activated the JAG1 luciferase reporter (Figure 5c ). These results, combined with the ChIP data, clearly indicate that the p63-53O hybrid efficiently transactivates p53AIP1. p53AIP1 siRNA antagonized the apoptotic effect of p63-53O To determine the significance of p53AIP1 on the proapoptotic effect of p63-53O in human cancer, we used siRNA to knockdown p53AIP1 expression in SW480 cells, which are relatively resistant to p53-mediated apoptosis. An siRNA lacking sequence homology to any human gene was used as a control, and cells were transfected with siRNA every 24 h for 3 consecutive days. As shown in Figure 6a , real-time RT-PCR demonstrated a reduction in p53AIP1 mRNA in cells transfected with p53AIP1 siRNA. At 8 h after the last transfection, the cells were infected with Ad-GFP or Ad-p63-53O for 48 h and subjected to immunoblot and caspase-3 assays. Pretreatment of SW480 cells with p53AIP1 siRNA robustly inhibited the p63-53O-mediated induction of p53AIP1 at the protein level (Figure 6b, upper panel) . Moreover, p53AIP1 siRNA antagonized the pro-apoptotic effects of p63-53O (Figure 6b , lower panel). These results suggest that the apoptotic effects of this hybrid protein are, at least in part, mediated through p53AIP1 activity. In summary, this hybrid efficiently activated transcription at the p53AIP1 promoter and induced apoptosis. Cancer gene therapy using p53-p63 hybrids Y Sasaki et al
DISCUSSION
In the present study, we took a novel approach to tumor suppression, constructing recombinant adenoviruses that express hybrid p53/TAp63g genes. We tested the proapoptotic ability of each of six hybrid constructs. Interestingly, one hybrid had a significantly higher proapoptotic activity than p53 or TAp63 and, as such, is a promising candidate for a 'super hybrid p53' approach to cancer gene therapy.
To evaluate the potency of each hybrid in suppressing tumor growth, we analyzed the induction of apoptosis after adenoviral infection. We observed a strong pro-apoptotic response to p63-53O as assessed by flow cytometry, caspase cleavage and caspase-3 activity. In a xenograft model in nude mice, the direct injection of Ad-p63-53O into pre-established tumors derived from SW480 or MKN45 cells resulted in significant growth retardation relative to the injection of Ad-p53 or Ad-p63g (Figure 4a and Supplementary Figure S6a) . TUNEL staining of xenograft tumors showed that the number of apoptotic cells was increased following Ad-p63-53O treatment, suggesting that the in vivo anti-tumor effects were mediated by an increase in apoptosis. The tumor-destroying mechanisms of cancer therapy depend primarily on the induction of apoptosis; therefore, our results demonstrate that gene therapy strategies based on this synthetic hybrid may be an effective molecular approach for cancer treatment. Previous studies reported that p53 family activity correlates with tumor cell sensitivity to certain DNA-damaging agents. 34, [36] [37] [38] [39] In general, gene therapy is given in combination with chemotherapy; p63-53O may have potential as a cancer gene therapy agent either alone or in combination with chemotherapeutic agents.
p53-mediated apoptosis depends primarily on the induction of a distinct class of transcriptional target genes, including BAX, PUMA, NOXA, p53AIP1 and others. 40 However, in clinical trials, the restoration of wild-type p53 gene function does not always lead to tumor regression or tumor growth inhibition, suggesting that certain tumors are resistant to exogenous p53. [31] [32] [33] 41 One potential mechanism for the robust pro-apoptotic activity of p63-53O involves the induction of p53AIP1. In all of the cell lines tested, p53AIP1 mRNA was more effectively induced by p63-53O than by p53. The ChIP and luciferase assay results indicate that p63-53O efficiently binds to the p53AIP1 promoter (Figures 5b Figure 5 . The p63-53O hybrid efficiently transactivated p53AIP1. (a) Four human cancer cell lines were infected with adenovirus at an MOI of 50 or 100, and the cells were harvested at 24 h after infection. Total RNA was extracted and subjected to northern blotting. Total RNA (10 mg) was loaded in each lane, and the same filter was rehybridized with human p53AIP1 and p21 cDNAs. Ethidium bromide staining of 28S ribosomal RNA (28S), shown in the lower panel, confirmed that equal amounts of RNA were loaded in each lane. (b) p63-53O interacts efficiently with the p53-RE in the p53AIP1 gene in vivo. The ChIP assay was performed as described in the Materials and methods. (c) p63-53O efficiently activates a p53AIP1 promoter that contains a p53-RE. SW480 cells were cotransfected with pGL3-p53AIP1-pro, pGL3-p53AIP1-ba, pGL3-p21 or pGL3-JAG1 and either a control pCMV-Tag2 vector or a vector that expresses p53, TAp73b, TAp63g, p63-53O or p63-53D. Luciferase activity was quantitated at 24 h after transfection, as described in the Materials and methods. Error bars represent two standard deviations calculated from three independent experiments. and c), leading to the upregulation of p53AIP1 and thus increased apoptosis. Knocking down p53AIP1 expression with siRNA diminished the pro-apoptotic effects of p63-53O (Figure 6 ), suggesting that p53AIP1 induction may underlie the distinct biological properties of this chimeric protein.
Through alternative promoter usage, p63 is expressed as one of two N-terminal isoforms and either contains (TA) or lacks (DN) a full TA domain. In general, the full-length TA isoforms exert p53-like activities, whereas the DN isoforms have the opposite effects. As a result of alternative splicing, multiple different C-termini are possible for these two N-terminal isoforms. TAp63 exists as three splice variants (TAp63a, TAp63b and TAp63g) of differing proapoptotic potency. The functions and properties of these isoforms are not fully understood. Differential splicing generates isoforms with or without a sterile a-motif (SAM) domain, which has been implicated in protein-protein interactions. 42 These distinct C-termini are also thought to modulate the transactivation of target gene expression by each TA isoform. The smaller isoforms, TAp63b and TAp63g, lack the SAM domain. In overexpression studies, TAp63g was as potent as p53 in inducing apoptosis. In contrast, the largest protein, TAp63a, had weaker transactivation and apoptotic activities than the other TA isoforms. The deletion of the C-terminal SAM domain restored the transactivation potential of TAp63a, suggesting that the C-terminal region of p63a reduces its activity. 43, 44 The p63-53O hybrid protein contains the N-terminal and central domains of TAp63 fused in-frame to the C-terminal domain of p53. Thus, replacing the C-terminal domain of TAp63 with that of p53 may increase the apoptotic potential of TAp63.
In conclusion, to enhance the tumor-suppressive activity of the p53 family, we generated a set of novel hybrid genes that take advantage of the differential regulation of p53 and p63. One hybrid, p63-53O, exhibited remarkable potency in suppressing tumor growth. FLAG-tagged p63-53O protein was expressed on the same level as FLAG-tagged p53 and p63g (Figure 3a) . The distinct C-termini (a, b and g) of the different TAp63 isoforms are known to modulate their ability to transactivate gene expression. Therefore, the p63-p53O hybrid consisting of the N-terminus and central DBD of p63 fused to the C-terminus of p53 has greater tumor suppressor activity probably due to its distinct spectrum of transcriptional activity from p53 and TAp63g (for example, p53AIP1). Although the identification of specific binding sequences using genome-wide ChIP assays is necessary to understand the hybrid's strong apoptotic activity, this synthetic tumor suppressor efficiently kills cancer cells and may be useful not only for cancer therapy but also for studies of apoptosis. Figure 6 . p53AIP1 siRNA antagonizes the induction of apoptosis by p63-53O. (a) The expression of p53AIP1 mRNA was inhibited by siRNA. SW480 cells were transfected with control or p53AIP1 siRNA every 24 h for 3 consecutive days. At 18 h after the last siRNA transfection, the suppression of p53AIP1 mRNA was determined by real-time RT-PCR. (b) SW480 cells were transfected with control or p53AIP1 siRNA as described above. At 8 h before the last siRNA transfection, cells were infected with Ad-GFP or Ad-p63-53O at an MOI of 100. The amount of p53AIP1 protein was determined by immunoblotting. Apoptosis was examined by caspase-3 cleavage (upper panel) and caspase-3 activity (lower panel).
